Puberty blocker

Uses your system voice; voice and rate in settings.

Snapshot

≈ 6 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Puberty blockers (also called puberty inhibitors or hormone blockers) are medicines used to postpone puberty. The most commonly used puberty blockers are gonadotropin-releasing hormone (GnRH) agonists, which suppress the natural production of sex hormones, such as androgens (e.g. testosterone) and estrogens (e.g. estradiol). Puberty blockers are used to delay puberty in children with precocious puberty. They are also used to delay the development of unwanted secondary sex characteristics in transgender youth, so as to allow them more time to explore their gender identity under what became known as the Dutch Protocol. The use of puberty blockers is supported by the Endocrine Society and the World Professional Association for Transgender Health (WPATH). In the United States, twelve major American medical associations, including the American Medical Association, the American Psychological Association, and the American Academy of Pediatrics support the use of puberty blockers. In Australia, four medical organizations support them. In the 2020s, the provision of puberty blockers for gender dysphoria in children has become the subject of public controversy, with the United Kingdom stopping the routine prescription of puberty blockers and some states of the United States making their use a criminal offense.…

Puberty blockers (also called puberty inhibitors or hormone blockers) are medicines used to postpone puberty. The most commonly used puberty blockers are gonadotropin-releasing hormone (GnRH) agonists, which suppress the natural production of sex hormones, such as androgens (e.g. testosterone) and estrogens (e.g. estradiol). Puberty blockers are used to delay puberty in children with precocious puberty. They are also used to delay the development of unwanted secondary sex characteristics in transgender youth, so as to allow them more time to explore their gender identity under what became known as the Dutch Protocol. The use of puberty blockers is supported by the Endocrine Society and the World Professional Association for Transgender Health (WPATH). In the United States, twelve major American medical associations, including the American Medical Association, the American Psychological Association, and the American Academy of Pediatrics support the use of puberty blockers. In Australia, four medical organizations support them. In the 2020s, the provision of puberty blockers for gender dysphoria in children has become the subject of public controversy, with the United Kingdom stopping the routine prescription of puberty blockers and some states of the United States making their use a criminal offense. In 2022, Sweden released updated national guidelines stating that puberty blockers should be limited to "exceptional cases". However, the guidelines do not constitute a ban.

Medical uses

Puberty blockers prevent the development of biological secondary sex characteristics. The same drugs are also used in fertility medicine and to treat some hormone-sensitive cancers in adults.

Precocious puberty

Puberty blockers are commonly used to delay puberty in children with precocious puberty, a condition that activates the hypothalamic-pituitary-gonadal axis prematurely and initiates puberty at an inappropriate age. The main goal of treatment is to preserve children's adult height potential. Puberty blockers work by stabilizing puberty symptoms, decreasing growth velocity, and slowing skeletal maturation. The outcomes of treatment are assessed in terms of height, reproduction, metabolic, and psychosocial measures. The most pronounced effects on height have been seen in children experiencing the onset of puberty before 6 years of age; however there is variability in height outcomes across studies which can be attributed to varying study designs, time of symptom presentation, and time of treatment termination. A study investigating the effects of puberty blockers on reproductive health showed no significant difference in the number of irregular menstrual cycles, pregnancies, or pregnancy outcomes between women who received treatment for precocious puberty and those who opted out of treatment. In terms of psychosocial markers, children diagnosed with precocious puberty have shown body image concerns and demonstrated poor emotional regulation and high anxiety. Individuals with precocious puberty, early adrenarche, and early normal puberty show less stress after treatment compared to individuals without preexisting developmental conditions. Overall, puberty blockers have demonstrated an excellent safety and efficacy profile for treating precocious puberty. The most common side effects reported include nonspecific headaches, hot flashes, and implant-related skin reactions.

Guidelines by country

Canada

The British Columbia Infants Act of 1996 grants minors legal decision-making authority if they can consent to a clinical intervention and their healthcare provider believes it is in their best interest. As a result, providers are required to evaluate if their patients have a robust and realistic understanding of hormone therapy, risks, benefits, and alternatives. Although some incorporate the gender-affirming care model into practice, others demonstrate reluctance to prescribe puberty blockers. A qualitative study investigating the experience of trans youth in seeking and receiving gender-affirming care at Canadian specialty clinics shows a mix of positive and negative outcomes. People reported improvements in their well-being, frustrations with treatment protocols and wait lists, and concerns with their transition journey. According to the Canadian Pediatric Society in 2024, "Current evidence shows puberty blockers to be safe when used appropriately, and they remain an option to be considered within a wider view of the patient's mental and psychosocial health."

Chile

The following medical organizations have expressed their support for puberty blockers for transgender children and adolescents: The Chilean Pediatric Society The Chilean Society of Psychiatry and Neurology of Childhood and Adolescence The Chilean Society of Childhood and Adolescent Gynecology

Second Trump presidency (2025–present)

Following a January 2025 executive order, United States Department of Health and Human Services (HHS) issued a declaration in December 2025 stating that gender‑affirming care for minors, including puberty blockers, is "neither safe nor effective" and does not meet recognized standards of care, and it announced steps to eliminate such care for individuals under 19 in federal programs. HHS guidance now promotes psychotherapy and psychosocial support instead of puberty blockers, hormones, or surgeries for pediatric gender dysphoria.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377556103 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

23 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.